Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
Vyvuz comes as an alternative that can be added to the current effort to tackle omicron
Bengaluru-based Atrimed Pharmaceuticals has recently launched their new find ‘Vyvuz Capsules’, a highly researched product licensed by the “Drug Authority of Kerala” that has been shown to inhibit the virus by up to 99.9%.
Dr. Hrishikesh Damle, M D & CEO – Atrimed Pharma stated that “With the ease of use and affordable price, all primary contacts, those who are travelling, attending gatherings or school-going children, can be protected against the virus with the addition of Vyvuz to existing measures.”
Since it is known to be safe, Vyvuz has ingredients that have been tested in the Government of India biotechnology labs and have been shown to inhibit the virus by up to 99.9%.
The formulation contains Centella Asiatica (Gotu kola), Withania Somnifera (Ashwagandha), and Andrographis Paniculata (bitterweed). Atrimed has conducted In-Silico, In-Vitro, In-Vivo, Phase 1 and Phase 2 clinical trials. The formulation was proven to be effective in reducing inflammatory markers and hence early symptomatic relief in COVID-19 patients.